Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience
- 24 June 2015
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 62 (11) , 1906-1913
Abstract
The use of intensive chemotherapy regimens in children with lymphoblastic lymphoma (LBL) has significantly improved outcome, but the salvage rate for these patients is still poor. The aim of this study was to evaluate the prognostic value of minimal disseminated disease (MDD), studied by multiparametric flow cytometry (MFC), in pediatric patients with T- and B-lineage LBL. We examined bone marrow (BM) and peripheral blood (PB) samples from a series of 65 children affected by T- (52) and B-lineage (13) LBL using an MFC method; 10 of them were also analyzed for clonality of T-cell receptor gene rearrangements. MDD was detected in 49% (32/65) of BM samples, whereas only 21% (14/65) were positive at standard morphological evaluation. Findings from MFC analyses of paired BM and PB samples were highly concordant. We analyzed the prognostic significance of MDD results detected at diagnosis in morphologically negative patients, as almost all relapsed cases (10/11) did not have any morphological involvement of BM at diagnosis. Using an MDD cut-off level of 3% by FCM (75th percentile), 5-year event-free survival (EFS) was 60% (SE ± 22) for patients with MDD >3% LBL cells versus 83% (SE ± 6) for the remaining patients (P = 0.04). No statistically significant difference in EFS was observed between LBL patients considering all the other clinical characteristics. Our data demonstrated that MDD studied at diagnosis by MFC could represent a useful prognostic tool in childhood LBL and further application for better stratification is warranted. Pediatr Blood CancerKeywords
Funding Information
- none reported.
This publication has 26 references indexed in Scilit:
- The immunophenotype of T‐lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group reportBritish Journal of Haematology, 2012
- Long‐term results of AIEOP LNH‐92 protocol for the treatment of pediatric lymphoblastic lymphoma: A report of the Italian Association of pediatric hematology and oncologyPediatric Blood & Cancer, 2009
- Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 studyLeukemia, 2009
- Shortened intensified multi‐agent chemotherapy and non‐cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology GroupBritish Journal of Haematology, 2008
- Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trialEuropean Journal of Cancer, 2008
- Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous System–Negative Stage III or IV Lymphoblastic LymphomaJournal of Clinical Oncology, 2006
- Signaling checkpoints during the development of T lymphocytesCurrent Opinion in Immunology, 1998
- Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non‐B‐cell (lymphoblastic) lymphomaMedical and Pediatric Oncology, 1992
- Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cellsNature, 1984
- Terminal Deoxynucleotidyl Transferase in Non-Hodgkin's LymphomaAmerican Journal of Clinical Pathology, 1983